HomeBUSINESS
BUSINESS

Tumor Regression Seen in 93% of RCC Patients on Lenvima-Keytruda Combo
(Sep.12.2017)

Tumor regression was seen in 93% of patients with renal cell carcinoma (RCC) receiving a combination therapy of Eisai’s multi-kinase inhibitor Lenvima (lenvatinib) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab), early-stage study data show ...
(LOG IN FOR FULL STORY)

News Calendar